UK-based molecular diagnostics firm Sense Biodetection has raised 拢12.3m for the development and manufacture of a range of instrument-free, point-of-care molecular diagnostic products.
The company has raised 拢10.5m through a Series A funding round, which was co-led by Cambridge Innovation Capital (CIC) and Earlybird.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Jonathan Milner and seed round investor Mercia Asset Management also took part in the funding round.
Along with the investment, Sense secured a grant of 拢1.8m from Innovate UK.
Sense Biodetection CEO Harry Lamble said: 鈥淲e are delighted to secure the funding necessary to conduct the formal development of our first products. With the support of an exceptional new investment syndicate, Sense is positioned to become first-in-class and best-in-class in the exciting field of instrument-free molecular diagnostics and to realise our vision to transform healthcare through decentralisation.鈥�
CIC’s Mike Anstey said: 鈥淲e鈥檙e delighted to co-lead Sense鈥檚 Series A financing, enabling this ambitious company to develop its pipeline of transformational products. CIC鈥檚 investment strategy is to build high-growth companies with differentiated, innovative technology within the Cambridge ecosystem, and Sense is a great example of this.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company uses rapid molecular amplification technology in its range of molecular diagnostics tests to target infectious disease applications such as influenza (flu).
According to the company, the field of molecular diagnostics is dominated by machine-based tests, but the systems and procedures needed to operate and maintain machines pose challenges at the point of care.
Sense Biodetection claim that its instrument-free molecular diagnostics could serve as a flexible test format given that it can be used by a wide range of potential users and in any setting.
The products can carry out rapid tests for viral and bacterial pathogens, such as those causing respiratory infections, within a short period.
